Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT03836443 |
Other study ID # |
D20180507 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
February 14, 2019 |
Est. completion date |
June 22, 2023 |
Study information
Verified date |
April 2023 |
Source |
Assistance Publique - Hôpitaux de Paris |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Nonalcoholic fatty liver disease (NAFLD) is mainly considered a nutrition-related disease and
life-style/diet interventions showed some promising results. But in spite of this, there are
no available markers to efficiently guide interventions. the hypothesize put farth by the
investigators is that NAFLD patients develop postprandial abnormalities of plasma lipids upon
"western diet" challenge, more severe in steatohepatitis (NASH) than in pure steatosis
(NAFL), promoting liver injury. Our study aims to evaluate the presence of toxic lipids (such
as free-fatty acids, ceramides, diacylglycerols, sphingolipids) in postprandial state after
ingestion of a "western diet" in NAFLD patients. Consecutive patients (group 1: NAFL
patients; group 2: NASH patients) with biopsy-proven NAFLD (liver biopsy < 6 months) will be
recruited during a period of 12 month. Blood samples will be drawn at fasting, 2hours,
4hours, 6hours and 8hours after ingestion of a "western diet" meal. Plasma lipid profiles
using lipidomics, circulating markers of liver injury and inflammation will be analyzed. the
investigators will also assess the hepatotoxicity of plasma from NAFL or NASH patients
in-vitro.
Description:
Factors driving progression from steatosis (NAFL) to steatohepatitis (NASH) in patients with
non-alcoholic fatty liver disease (NAFLD) remain largely unknown. Considerable data now
indicate that steatosis per se is not a hepatotoxic event and may represent in fact a
protective mechanism against free fatty acid (FFA)-induced toxicity. the investigators
previously showed that Kupffer cells from NASH mice accumulate more toxic lipids (ceramides,
diacylglycerols, sphingolipids) enhancing their proinflammatory polarization. Therefore,
"quality" of accumulating lipids rather than "quantity" may play a central role in NAFLD
progression. This is a pilot comparative study aiming to evaluate the presence of toxic
lipids (such as free-fatty acids, ceramides, diacylglycerols, sphingolipids) in postprandial
state after ingestion of a "western diet" in NAFL and NASH patients. The secondary outcomes
were: to evaluate the relationship between postprandial circulating lipids and markers of
liver injury and proinflammatory cytokines; to evaluate hepatotoxicity of postprandial lipids
in vitro. A total of 24 consecutive patients (group 1: 12 NAFL patients; group 2: 12 NASH
patients) with biopsy-proven NAFLD (liver biopsy < 6 months) will be recruited. A dietary
evaluation covering the 2 previous weeks will be performed. Detailed anthropometric data will
be collected (body mass index, waist and hip circumferences, abdominal height, cutaneous
skinfolds) and serum metabolic parameters (standard lipid profile, lipoprotein levels,
fasting plasma glucose, insulin levels, C-peptide levels, hemoglobin A1c) will be evaluated.
After a 12hours overnight fast, patients will undergo an oral "western diet" test consisting
in the ingestion of a high saturated fat, high refined sugar, high fructose-meal called
"western diet" (800 kcal/meal). Blood samples will be drawn at fasting and then 2, 4, 6 and
8hours after ingestion of the standard meal. Each time plasma and serum samples will be
stored at -80°C for subsequent analysis. Lipidomics will be used to quantify each plasma
lipid class (neutral lipids, phospholipids and fatty acid methyl esters). Serum levels of
cytokines will be assessed using multiple assay technology. Markers of liver injury will be
assessed (aminotransferases, Keratin 18 fragments, microRNA-122) in the serum. Hepatocytes
will be cultured with plasma from NAFL or NASH patients, and incubated overnight. In vitro
hepatotoxicity will be evaluated using TUNEL assay, MTT assay and LDH release assay. the
investigators anticipate that inflammation together with hepatocyte death will occur in NAFLD
patients who develop specific postprandial plasma lipid changes with an increase in toxic
lipid levels. Such patients may develop more severe liver lesions (inflammation,
fibrosis/cirrhosis) and benefit of interventions. Identification of a toxic plasma lipid
profile may help choosing the adequate diet in order to prevent deleterious lipid formation.
Identification of a toxic postprandial plasma lipid signature specific to hepatotoxicity may
also serve to develop a discrimination index to be further validated in clinical practice.